Northpointe Capital’s Impax Laboratories, Inc. IPXL Stock Holding History

Northpointe Capital’s Portfolio IPXL Stock Details IPXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-77,705	Closed	-$3.64M	–	258
2015 Q1	$3.64M	Hold	77,705	–	–	0.39%	86
2014 Q4	$2.46M	Buy	+77,705	New	+$2.27M	0.3%	117
2014 Q3	–	Sell	-86,080	Closed	-$2.58M	–	281
2014 Q2	$2.58M	Sell	86,080 -1,000	-1%	-$27K	0.25%	111
2014 Q1	$2.3M	Buy	87,080 +10,150	+13%	+$254K	0.23%	102
2013 Q4	$1.93M	Buy	+76,930	New	+$1.72M	0.17%	122

Other funds holding IPXL

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Hound Partners New York $799M AUM 9.54% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

PCM

Pennant Capital Management Summit, New Jersey $212M AUM 19.37% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Aravt Global New York $11.3M AUM 3.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

Northpointe Capital's IPXL Position: Q2 2015 in Review

Northpointe Capital sold out of Impax Laboratories, Inc. (IPXL) in Q2 2015, closing a stake of 77,705 shares — an estimated $3.64M sold.

Northpointe Capital first reported a position in IPXL in Q4 2013 and held it in 5 quarters. The position peaked at $3.64M in Q1 2015. 197 funds tracked by Wall St. Rank hold IPXL as of Q2 2015.

Northpointe Capital reported no remaining Impax Laboratories, Inc. position as of Q2 2015 after selling out during the quarter.
Northpointe Capital sold 77,705 Impax Laboratories, Inc. shares in Q2 2015, an estimated $3.64M.
Northpointe Capital first reported a position in Impax Laboratories, Inc. in Q4 2013 and held it in 5 quarters.
Northpointe Capital's Impax Laboratories, Inc. position peaked at $3.64M in Q1 2015.
197 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q2 2015.

Based on Northpointe Capital's 13F filing for Q2 2015, filed 30 Jul 2015.